Lumican (LUM) is one of the type II SLRPs, and its expression is significantly increased in a variety of tumors, especially lung cancer, gastric cancer, colon cancer, pancreatic cancer and bladder cancer (11–15). Here, LUM is linked to urinary bladder cancer.